suicide gene therapy of glioma using genetically engineered bone marrow-derived mesenchymal stem cells

研究了利用骨髓间充质干细胞（MSC）和更昔洛韦（GCV）进行自杀基因治疗，以治疗目前治疗困难的恶性脑肿瘤。用导入单纯疱疹病毒胸苷激酶（HSVtk）的MSC（MSCtk）对大鼠C6脑肿瘤细胞进行治疗。在体外实验中，MSCtk：C6细胞比例高达1：128，肿瘤完全消退的效果达到1：32。在用培养显微镜观察时，观察到MSCtk存活48小时或更长时间的外观，并观察到旁观者效应持续。在体内，在使用大鼠的研究中，证实了肿瘤减少效果和存活曲线的延长。在安全性验证中，在体外，MSCtk/GCV处理原代培养的神经元和胶质细胞，对正常脑细胞无影响。在体内，虽然治疗大鼠通过时间和组织学恢复，但不承认对正常脑细胞的影响。认为MSCtk/GCV治疗是一种安全有效的治疗方法。

The suicide gene therapy using mesenchymal stem cells (MSC) and ganciclovir (GCV) was researched to the malignant brain tumor that has a hard time in treatment. Treatment was tried by using MSC that introduced herpes simplex virus-thymidine kinase (HSVtk) (MSCtk) for rat C6 brain tumor cell. In vitro, The ratio of cells of MSCtk:C6 showed as many as 1:128 antitumor effects, and an effect of the tumor extinction complete by 1:32 was achieved. In the observation with the culture microscope, MSCtk was observed and the appearance to which it lived for 48 hours or more, and the bystander effect continued was observed. In vivo, in the research that used the rat, the extension of the effect of the tumor reduction and the survivorship curve was confirmed. In the confirmation of safety, in vitro, the influence on the normal brain cell is not seen though MSCtk/GCV was treated on the primary culture of neuron and glia. In vivo, the influence on the normal brain cell was not admitted though the treatment rat was passing time and histology retrieved. It was thought that the MSCtk/GCV treatment was effective and a safe therapy.